CDMOs: Your Technical Capabilities Are World-Class. Does Your Marketing Reflect That?

A Market Full of Opportunity, and Full of Noise

I spend a considerable amount of time reviewing how CDMOs present themselves to the market, and what I find consistently is a significant gap between the depth of capability that exists inside these organisations and the way that capability is communicated externally. The global CDMO market is valued at approximately USD 255 to 275 billion in 2025 and 2026, with projections pointing toward a potential doubling of market size by the mid-2030s. Biologics manufacturing, cell and gene therapy, antibody-drug conjugates, GLP-1 peptide manufacturing, and complex injectables are all generating real commercial urgency.

The tailwinds are strong. But the same forces driving demand are also drawing new entrants, accelerating M&A activity, and raising client expectations across the board. Winning business in this market is no longer simply about having the right technical capabilities. It is about being known for them, being trusted with them, and communicating both with the clarity and confidence that earns a first conversation, and then a long-term relationship.

What Pharma Sponsors Are Actually Looking for When They Choose a CDMO

One of the most important shifts in the CDMO market over the past few years is the growing expectation among sponsors that they are selecting a strategic partner, not procuring a manufacturing service. Small and emerging biotech companies, which sponsored 32% of innovative drug approvals over the past decade, are specifically looking for CDMO partners who can function as extensions of their development teams. They need partners who are technically excellent, but also nimble, transparent, and genuinely invested in the success of the program.

Larger pharmaceutical companies are taking an even more deliberate view of CDMO relationships. Following the passage of the BIOSECURE Act and the sustained attention to supply chain resilience, approximately 120 US drugs currently rely on Chinese CDMOs for some component of their manufacturing, and companies are taking a long-term approach to restructuring those dependencies. Sponsors are scrutinising potential partners not just on technical capability, but on regulatory track record, quality system maturity, supply chain robustness, and cultural alignment with their own operating standards.

If your marketing does not communicate credibly across all of these dimensions, you are leaving evaluators to fill in the gaps with assumptions, or worse, with a competitors pitch.

The Differentiation Problem Is Real, and It Is Costing You Business

I want to name something that I think most CDMO commercial leaders already know but rarely address directly: the majority of CDMO websites and marketing materials read nearly identically. Flexible capacity, global reach, quality systems, regulatory expertise, integrated services, dedicated teams. These are not wrong claims. They are simply not differentiating. They do not give a program director at a biotech the specific reassurance they need to bring a first-in-class molecule to a new manufacturing partner on a tight development timeline.

The CDMOs building the strongest commercial pipelines are investing in a fundamentally different approach to their marketing. They publish technical content that demonstrates genuine scientific depth in their areas of core specialisation, whether that is high-potency APIs, mRNA manufacturing, continuous processing, complex injectables, or advanced modalities. They build thought leadership content that showcases the expertise of their scientific and operations teams, not just the specifications of their facilities. And they develop case study content that brings their problem-solving culture and collaborative approach to life in ways that a capabilities brochure simply cannot.

Your Digital Presence Is the First Round of Due Diligence

Business development in the CDMO sector has historically been built on conference relationships, referral networks, and direct outreach programs. Those channels remain important and should not be abandoned. But the reality in 2026 is that the first filter for the majority of sponsor evaluations happens before any call is ever scheduled. Development teams search. They read. They assess your scientific credibility through your published content. They evaluate your depth in their specific modality through your white papers and technical resources. They form a view of your organisation's culture and responsiveness through your digital touchpoints, often weeks before anyone reaches out.

CDMOs that treat their website as a static brochure are forfeiting early-stage brand consideration to competitors who have made the investment in their digital presence. A content strategy built around the specific questions your ideal client is asking at each stage of their decision process, from modality selection through to partner qualification, is one of the highest-return commercial investments a CDMO can make right now.

Turning Technical Excellence into Commercial Momentum

The CDMOs generating the most qualified inbound commercial pipeline right now have made a deliberate choice to invest in their brand with the same seriousness they invest in their facilities. They have clear, specific positioning that differentiates them within their areas of specialisation. They have content programs that speak directly to the concerns and criteria of their ideal client profiles. And they build visibility consistently at the moments that matter most in the sponsor decision process.

At VELLUM, we work with CDMOs and contract manufacturing organisations to build marketing strategies that translate technical capability into commercial advantage. From positioning and messaging architecture through to content programs, digital presence, and lead generation, we help you tell the story that turns first conversations into long-term partnerships.

Is your marketing keeping pace with your capabilities? Contact VELLUM to find out how we can help.

About VELLUM Global

VELLUM is a life sciences-focused marketing agency serving companies across Medical Devices & Diagnostics, Pharmaceuticals & Biologics, OTC & Consumer Health, Cosmetics & Specialty Chemicals, Food & Nutritional Supplements, Laboratory Equipment & Scientific Instruments, CDMOs & Manufacturing Organizations, and Regulatory & Consulting Organizations. We combine strategic intelligence, scientific credibility, and marketing craft to help our clients build meaningful brands, generate qualified leads, and grow commercially in one of the world's most consequential industries.